SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Cathcart who wrote (386)	6/24/1999 9:21:00 AM
From: scaram(o)uche	Read Replies (2) of 579

Yes!! Thanks, David. Again, I can't find prior art. off topic....... It looks like Merck is going to have some early data, Vioxx over Celebrex. If you have friends that are taking Celebrex, you might tell them. Also, Searle has a second generation cox-2 inhibitor coming, and Lilly SCIO have a second generation PDE5 inhibitor in phase III. Seems like Pfizer, recently scrambling to do good deals with NRGN and ABSC, not only has a problem with the pipe in five years, but is dangerously open to criticism right now. I asked this in another thread..... cox-2 inhibitors are supposed to differ from aspirin, among other characteristics, in that they have lower affinity for cox-1 and therefore don't harm the stomach. But FDA has not given Searle/Pfizer or Merck the labeling that they want. Is everyone certain that there's no description of gastropathy due to celecoxib (Celebrex)?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next